NICE green light for Roche’s Rozlytrek
The drug targets all solid tumours with the NTRK gene fusions
Read More
Tag: NTRK
NICE issues final guidance on NHS use of Bayer’s Vitrakvi
Evidence from trials suggests that tumours with NTRK gene fusions shrink in response to larotrectinib
Read More
Bayer/Loxo’s larotrectinib gets speedy review in the US
Bayer/Loxo Oncology’s larotrectinib has been granted a priority review by the US Food and Drug Administration, which will consider its use to treat metastatic solid tumours carrying a certain genetic mutation.
Read More
Roche to buy Ignyta for $1.7 billion
Roche has announced plans to buy US group Ignyta for $27 a share in an all-cash deal totaling around $1.7 billion, securing itself access to the latter’s experimental cancer medicines.
Read More
Horizon expands agreement with Roche Diagnostics
Cambridge, UK-based Horizon Discovery has expanded its relationship with Roche Diagnostics with a new agreement to assist in the development of immunohistochemistry (IHC) assays.
Read More
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
